RAPP Q4 2024 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

RAPPRapport Therapeutics, Inc. Common Stock

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$24M

Net Income

-$20M

EPS (Diluted)

$-0.10

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$315M

Total Liabilities

$10M

Stockholders' Equity

$305M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$76,000	+100.0%
Operating Income	-$24M	-$15M	-59.0%
Net Income	-$20M	-$14M	-47.8%